NCT01220141 - Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia B

Interventions

DRUG

activated recombinant human factor VII

Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.

Trial Locations (14)

1025

Budapest

1070

Brussels

55127

Mainz

92932

Paris La Défense Cedex

B1636DSU

Prov. de Buenos Aires

A-1010

Vienna

Unknown

Tehran

Dublin

00144

Rome

PL-02-274

Warsaw

2780-730

Paço de Arcos

811 05

Bratislava

202 15

Malmo

RH11 9RT

Crawley